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Extensive changes in resting-state oscillatory brain activity have recently been demonstrated using magneto-
encephalography (MEG) in moderately advanced, non-demented Parkinson’s disease patients relative to age-
matched controls. The aim of the present study was to determine the onset and evolution of these changes
over the disease course and their relationship with clinical parameters. In addition, we evaluated the effects of
dopaminomimetics on resting-state oscillatory brain activity in levodopa-treated patients. MEG background
oscillatory activity was studied in a group of 70 Parkinson’s disease patients with varying disease duration and
severity (including 18 de novo patients) as well as in 21 controls that were age-matched to the de novo patients.
Whole head 151-channel MEG recordings were obtained in an eyes-closed resting-state condition. Levodopa-
treated patients (N¼ 37) were examined both in a practically defined ‘OFF’ as well as in the ‘ON’ state.
Relative spectral power was calculated for delta, theta, low alpha, high alpha, beta and gamma frequency
bands and averaged for 10 cortical regions of interest (ROIs). Additionally, extensive clinical and neuropsycholo-
gical testing was performed in all subjects. De novo Parkinson’s disease patients showed widespread slowing of
background MEG activity relative to controls. Changes included a widespread increase in theta and low alpha
power, as well as a loss of beta power over all but the frontal ROIs and a loss of gamma power over all but the
right occipital ROI.Neuropsychological assessment revealed abnormal perseveration in de novo patients, which
was associated with increased low alpha power in centroparietal ROIs. In the whole group of Parkinson’s disease
patients, longer disease duration was associated with reduced low alpha power in the right temporal and right
occipital ROI, but not with any other spectral power measure. No association was found between spectral
power and disease stage, disease severity or dose of dopaminomimetics. In patients on levodopa therapy, a
change from the ‘OFF’ to the ‘ON’ state was associated with decreases in right frontal theta, left occipital beta
and left temporal gamma power and an increase in right parietal gamma power.Widespread slowing of oscilla-
tory brain activity is a characteristic of non-demented Parkinson’s disease patients from the earliest clinical
stages onwards that is (largely) independent of disease duration, stage and severity and hardly influenced by
dopaminomimetic treatment. Some early cognitive deficits in Parkinson’s disease appear to be associated
with increased low alpha power.We postulate a role for hypofunctional non-dopaminergic ascending neurotrans-
mitter systems in spectral power changes in non-demented Parkinson’s disease patients.
Keywords: Parkinson’s disease; magnetoencephalography (MEG); resting-state; oscillations; spectral analysis
Abbreviations: EEG¼Electroencephalography; MEG¼Magnetoencephalography
Received October 4, 2006. Revised February 1, 2007. Accepted February 12, 2007. Advance Access publication April 5, 2007
Introduction
In patients with Parkinson’s disease with dementia,
considerable diffuse slowing of resting-state oscillatory
brain activity has consistently been reported in comparison
to both non-demented Parkinson’s disease patients as well
as healthy controls. Electroencephalography (EEG) and
magnetoencephalography (MEG) studies in demented
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patients generally show increases in delta and theta activity
and decreases in alpha and beta activity (Neufeld et al.,
1988; Soikkeli et al., 1991; Neufeld et al., 1994; Tanaka
et al., 2000; Sinanovic et al., 2005; Bosboom et al., 2006).
Until very recently, the presence of slowing of resting-state
oscillatory brain activity in non-demented Parkinson’s
disease patients was a more controversial issue. Generally,
EEG studies in non-demented Parkinson’s disease patients
have not shown (pronounced) slowing of resting-state brain
activity (Neufeld et al., 1994; Gagnon et al., 2004; Sinanovic
et al., 2005). Some older studies, however, have shown a
slowing of the occipital background rhythm (Neufeld et al.,
1988; Soikkeli et al., 1991), a decrease of beta power
(Pezard et al., 2001) and, remarkably, an increase in alpha
power (Tanaka et al., 2000) in non-demented Parkinson’s
disease patients relative to controls. In one MEG study, in
which cognitive status was unfortunately not reported, a
decreased frequency of the dominant alpha rhythm and an
increase in low frequency power were found (Kotini et al.,
2005). In a very recent MEG study, we were the first to
demonstrate extensive changes in resting-state oscillatory
brain activity also in non-demented Parkinson’s disease
patients at moderately advanced stages of disease (mean
subjective disease duration 9.7 4.5 years) relative to age-
matched controls (Bosboom et al., 2006). The exact time of
onset of slowing of resting-state oscillatory brain activity in
Parkinson’s disease and its evolution over the disease
course, however, are still unknown.
Brain processes not only require the activation of
specialized brain areas but also some mechanisms to integrate
their activity. There is increasing evidence from neurophys-
iological studies that synchronized oscillatory neuronal
activity plays a crucial role in integrating higher brain
processes (Schnitzler and Gross, 2005). As adequate brain
function requires the integration of specialized brain areas,
clinical deficits in neurological diseases such as Alzheimer’s
disease and Parkinson’s disease are expected to be associated
with changes in oscillatory brain activity (Schnitzler and
Gross, 2005). In Alzheimer’s disease, which is also character-
ized by a diffuse slowing of resting-state oscillatory brain
activity, measures of global cognition such as Folstein’s Mini-
Mental State Examination [MMSE (Folstein et al., 1975)], as
well as more specific neuropsychological test scores are
associated with slowing of resting-state oscillatory brain
activity (for a review of EEG dynamics in patients with
Alzheimer’s disease, see Jeong, 2004). With the noteworthy
exception of studies using intra-cerebral recordings in
Parkinson’s disease patients undergoing functional neurosur-
gery, only a few studies have reported associations of (changes
in) resting-state oscillatory brain dynamics with clinical
(motor or cognitive) parameters in demented or non-
demented Parkinson’s disease patients. To our knowledge,
only a single study has reported an association between disease
(motor) severity and oscillatory brain dynamics; Neufeld
and co-workers found the degree of motor disability to be
associated with the frequency of slowing of occipital
background activity in mentally intact patients (Neufeld
et al., 1988), which they interpreted as an indication that
subcortical structures (involved in motor control) can
influence occipital background activity. Two studies have
reported associations between spectral power and cognitive
parameters: Sinanovic and co-workers found slowing of
background activity to be associated with lower MMSE scores
in demented Parkinson’s disease patients (Sinanovic et al.,
2005). In the MEG study by Bosboom and co-workers
(Bosboom et al., 2006), increased theta power in occipital and
right temporal channels was associated with lower scores on a
measure of global cognitive function [CAMCOG scale (Roth
et al., 1986; Hobson and Meara, 1999)] in non-demented
Parkinson’s disease patients. To our knowledge, no study has
explored the relationship of more specific measures of
cognitive performance with oscillatory brain activity in non-
demented (or demented) Parkinson’s disease.
An important neuropathological feature of Parkinson’s
disease is a dopamine (DA) deficit in the striatum, which
results in abnormal basal ganglia outflow to the (pre)frontal
cortex. In addition, degeneration of the mesocortical
dopaminergic system in Parkinson’s disease produces a loss
of DA terminals in the (pre)frontal cortex itself. Either of these
two pathological features of Parkinson’s disease might
constitute the mechanism behind changes in oscillatory
brain activity and (frontal) cognitive dysfunction. The role
of the nigrostriatal dopaminergic projection in cognitive
function is supported by a functional magnetic resonance
imaging (fMRI) study, in which a specific effect of
dopaminergic manipulation on the effective connectivity
between the caudate and the ventral midbrain was found in
healthy subjects (Honey et al., 2003). An EEG study showed
Parkinson’s disease to be associated with impaired cortical
connectivity that could be normalized by levodopa treatment
(Cassidy and Brown, 2001). Assuming that the dopaminergic
deficit in Parkinson’s disease is a key factor in causing
alterations of oscillatory brain activity, restoring brain
dopamine levels by drug treatment should at least partly
restore normal patterns of oscillatory brain activity.
According to a newly introduced neuropathological
staging system for Parkinson’s disease (Braak et al., 2003),
degeneration of nuclei that give rise to ascending cortico-
petal neurotransmitter systems is one of the earliest
pathological features of Parkinson’s disease. This includes
not only the dopaminergic neurons in the substantia nigra,
but also noradrenergic neurons in the locus coeruleus and
serotonergic neurons in the dorsal raphe nuclei.
Interestingly, involvement of the corticopetal non-dopami-
nergic projection systems may even precede degeneration of
dopaminergic substantia nigra neurons. In these very early
pathological stages of Parkinson’s disease, the forebrain
cholinergic system arising from the basal nucleus of
Meynert is affected to a much lesser extent. Degeneration
of noradrenergic and serotonergic corticopetal projection
systems may therefore at least contribute to any early stage
alterations in cortical oscillatory brain activity.
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In the present study, we set out to determine whether
changes in resting-state oscillatory brain activity occur
already in the earliest clinical stages of Parkinson’s disease,
before the start of dopaminergic treatment. In addition, we
aimed to study the effects of disease duration, disease stage,
disease severity and dopaminergic medication on the
observed changes, as well as the relationship of any
alterations in spectral power with changes in cognitive
function.
Material and Methods
Subjects
A total of 84 patients with idiopathic Parkinson’s disease
diagnosed according to the United Kingdom Parkinson’s Disease
Society Brain Bank (UK-PDSBB) clinical diagnostic criteria
(Hughes et al., 1992) were recruited from the outpatient clinic
for movement disorders at the VU University Medical Center
(VUMC). Parkinson’s disease patients were recruited pseudo-
randomly as they were selected on the basis of their (subjective)
disease duration and use of medication and concurrently classified
into two groups; de novo Parkinson’s disease patients (untreated,
subjective disease duration 52 years) and early to moderately
advanced Parkinson’s disease (all other patients with a subjective
disease duration 514 years). A group of 21 self-declared healthy
controls, who were age-matched to the de novo Parkinson’s disease
patients, was composed of spouses of the patients as well as of
other healthy volunteers. All subjects were screened for neurolo-
gical disorders by a trained physician. Exclusion criteria for
Parkinson’s disease patients were stereotactic surgery in the past
and the current use of psychoactive compounds such as
antipsychotics, antidepressants, anticholinergics, cholinesterase
inhibitors, benzodiazepines and stimulants. Eleven Parkinson’s
disease patients were excluded from further analysis due to
irremediable artefacts during MEG registration, usually caused by
dental implants. Two other Parkinson’s disease patients were
excluded on the basis of MRI findings: one patient with extensive,
probably ischaemic cerebral white matter lesions in frontal and
parietal areas and a patient with a tumour of the pituitary gland.
Additionally, one patient exhibited cognitive deficits interfering
with activities of daily living (ADL) and was as such suspected
of (developing) dementia, leaving a total of 21 controls and
70 Parkinson’s disease patients, including 18 de novo and 37
levodopa-treated Parkinson’s disease patients, for further analysis.
Subject characteristics
Level of education was determined using a standard
Dutch educational scale [SOI-2003 (Centraal Bureau voor
Statistiek, 2003)] which was subsequently converted to the
International Standard Classification of Education [ISCED-1997
(UNESCO, 1997)]. Verbal IQ was measured using the Dutch version
of the National Adult Reading Test [NART (Nelson and O’Connell,
1978; Schmand et al., 1991)]. The NART yields a good estimate of the
pre-morbid level of intelligence of cerebrally damaged patients
(Bright et al., 2002). Global cognitive function and the
presence of dementia were examined using the CAMCOG scale
(Roth et al., 1986; Hobson and Meara, 1999). None of the
patients fulfilled DSM-IV-TR clinical diagnostic criteria for demen-
tia (American Psychiatric Association, 2000), which was also
evidenced by scores above 78 out of a total of 107 points on the
CAMCOG scale. Disease duration was calculated on the basis of
the patients’ subjective estimate of the time of occurrence of the
first motor symptoms, which has been shown to have high
convergent reliability both with medical records as well as with an
estimate derived from a structured face-to-face interview by
a medical professional (Reider et al., 2003). Side of onset was based
on the body-half in which the first motor symptoms occurred.
Unified Parkinson’s Disease Rating Scale [UPDRS-III, (Fahn et al.,
1987)] motor scores and modified Hoehn and Yahr stages
(Jankovic et al., 1990) were obtained by a trained physician.
Additionally, total tremor score was determined by summing
scores on tremor-related items of the UPDRS-III (items 20
and 21). The total daily dose of dopaminomimetics was converted
to a so-called levodopa equivalent daily dose (LEDD) using the
following conversion rate: 100 mg levodopa equalling 125 mg
levodopa sustained release, 1 mg pergolide, 1 mg pramipexol or
6 mg ropinirole. Additionally, 5% was added to the total
levodopa dose for every 5 mg of selegiline, up to a maximum of
10%. Levodopa was always used in combination with a peripheral
decarboxylase inhibitor. None of the patients had severe motor
response fluctuations or exhibited serious dyskinesias during
testing. All subjects gave written informed consent to
the research protocol, which was approved by the local medical
ethical committee of the VUMC. Ethics review criteria conformed
to the Helsinki declaration. Subject characteristics are listed in
Table 1.
MRI
MR imaging on a Siemens Magnetom Impact Expert 1.0 T system
(Siemens AG, Erlangen, Germany), using an MP-RAGE and
fast-FLAIR scanning sequence, was performed in all subjects in an
attempt to exclude other potential causes of parkinsonism as well
as major brain pathology such as tumours and relatively large
cerebrovascular lesions [early confluent or confluent, Fazekas score
higher than 1 (Fazekas et al., 1987)]. Vascular lesions at the level
of the basal ganglia on fast-FLAIR MR images were considered
supportive of vascular parkinsonism. A hypointense putamen with
a hyperintensive rim and/or hyperintensities in the brainstem on
fast-FLAIR images were considered supportive of multiple system
atrophy. All MR images were reviewed by a radiologist specialized
in neuroradiology.
Specific neuropsychological evaluation
Specific cognitive, mainly executive (frontal) functions were
assessed using a comprehensive set of neuropsychological tasks.
Six tasks were taken from the Cambridge Neuropsychological Test
Automated Battery (CANTAB Eclipse 2.0, Cambridge Cognition,
Cambridge, UK), a series of extremely well standardized and
validated computerized paradigms. This battery includes an
introductory motor screening task which acts as a training
procedure for the other tasks and yields measures of both speed
and accuracy that provide an index of the subjects’ motor skill.
Other tasks included in the battery are spatial span (spatial short-
term memory), spatial working memory (working memory,
strategy), stockings of Cambridge (working memory, planning)
and intra-dimensional/extra-dimensional shift (set-shifting). These
tasks are known to be (selectively) sensitive to cognitive deficits in
Parkinson’s disease and Parkinson’s disease-related dementia (for
a review, see Robbins et al., 2002). An additional two tasks were
taken from the Vienna Test System version 6.0 (Dr G. Shuhfried
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GmbH, Mo¨dling, Austria). To assess abstract reasoning, the
Vienna version of Raven’s standard progressive matrices was
administered. This computerized version is particularly well suited
for non-verbal assessment of the ‘eductive’ (analytical, reasoning)
component of general intelligence (Raven et al., 2000). To assess
the amount of perseveration in the generation of random motor
behaviour, the Vienna Perseveration Task was administered. This
computerized version of the pointing task by Mittenecker (1958)
is ideally suited for measuring the internal control of behaviour,
since this task does not contain any external cues. Previous
research in our department has shown the task to be sensitive to
cognitive dysfunction in Parkinson’s disease, even at the earliest
clinical stage (Stoffers et al., 2001). Verbal fluency was assessed
using the 1 min categorical fluency test (animals) which is part of
the CAMCOG scale (Roth et al., 1986; Hobson and Meara, 1999).
MEG data acquisition
MEG data were acquired using a 151-channel whole-head radial
gradiometer MEG system (CTF Systems Inc., Port Coquitlam, BC,
Canada). Average distance between sensors in this system is
3.1 cm. Patients were seated in a magnetically shielded room
(Vacuum-schmelze GmbH, Hanau, Germany). The recording
pass-band was 0.25–125 Hz with a sample rate of 312.5 Hz.
A third-order software gradient (Vrba et al., 1999) was applied.
Patients treated with levodopa were instructed to come to the
hospital without taking their first morning dose of anti-Parkinson
medication, which ensured that this registration was carried out at
least 9 h after the last dose of dopaminomimetics (practically
defined ‘OFF’). To assess the acute effect of dopaminomimetics on
spectral power, a second registration was performed in patients
treated with levodopa at least 1 h after the normal morning dose
of anti-Parkinson medication had been taken (‘ON’ state). At the
beginning of the measurement, head position relative to the
coordinate system of the helmet was recorded by leading small
alternating currents through three position coils situated at the left
and right pre-auricular points and the nasion on the subject’s
head. MEG was recorded in an eyes-closed resting-state condition
and during the performance of two executive tasks. Task-related
data were not analysed in the current study.
MEG data analysis
Three 13.083 s epochs per registration (sample rate 312.5 Hz; 4096
samples per epoch), free of significant artefacts involving multiple
adjacent channels, were selected for further analysis by two of the
investigators blinded for the clinical diagnosis (D.S. and J.L.W.B.).
Of the original 151 channels, one channel above the left occipital
region was excluded in all patients because of technical problems
during the recordings. For further off-line processing and spectral
power analysis epochs were converted to ASCII-files and imported
into the DIGEEGXP 2.0 software package (C.J. Stam, Amsterdam,
The Netherlands). Subsequently, the MEG data were digitally
filtered off-line with a band-pass of 0.5–48 Hz. Relative spectral
power was determined in the following frequency bands: 0.5–4 Hz
(delta), 4–8 Hz (theta), 8–10 Hz (low alpha), 10–13 Hz (high
alpha), 13–30 Hz (beta) and 30–48 Hz (gamma). The MEG
channels were grouped into regions of interest (ROIs) roughly
corresponding to the major cortical areas (frontal, central,
temporal, parietal and occipital) on the left and right side of the
brain. As ROIs were based on the extra-cranial position of the
MEG sensors, underlying cortical areas are to be considered as
indicative. The nine midline channels were left out of this
clustering, leaving a total of 141 channels divided over 10 ROIs for
analysis (Fig. 1). In a small number of subjects in both the control
(N¼ 5) and patient (N¼ 8) groups, four channels showed
artefacts of a technical nature during visual inspection of the
epochs (i.e. dysfunctional super-conducting quantum interference
device or channel amplifier, yielding a high frequency, high-
amplitude signal). These channels were located in the left frontal
and left central (N¼ 7 subjects), left occipital (N¼ 5 subjects) and
right temporal (N¼ 1 subjects) ROIs. Power values for the
respective individual channels in these particular subjects, as well
as for the earlier mentioned left occipital MEG channel in all
subjects, were left out of the averaging, ensuring that the
mean relative power in the ROI containing the bad channel
Table 1 Subject characteristics
Controls
(N¼ 21)
All Parkinson’s disease
patients (N¼ 70)
De novo Parkinson’s disease
patients (N¼18)
Levodopa-treated
Parkinson’s disease
patients (N¼ 37)
Age (years, mean SD) 59.4 7.3 62.16.8 59.4 7.9 63.5 6.6
Sex (8/9) 11/10 40/30 12/6 18/19
Education (ISCED 0/1/2/3/4/5/6) 0/0/6/4/2/8/1 1/0/27/16/4/21/1 0/0/5/5/0/8/0 0/0/18/6/3/9/1
Verbal IQ (Dutch NART) 111.7 9.4 107.713.1 109.211.2 106.614.1
Global cognition (CAMCOG) 98.9 4.2 97.0 5.1 98.24.7 96.5 5.7
Disease duration (years, mean SD) n.a. 5.53.7 0.9 0.5 8.0 2.7
Side of onset (left/right) n.a. 33/37 4/14 21/16
H&Ymodified ‘OFF’ (1/1½/2/2½/3) n.a. 14/1/29/18/8 9/1/7/1/0 1/0/16/12/8
UPDRS-III ‘OFF’ (mean SD) 0.61.4 17.16.9 13.16.1 19.16.8
UPDRS-III ‘ON’ (mean SD) n.a. n.a. n.a. 12.6 4.6
LEDD DA agonists (mg) n.a. 171183 n.a. 285168
LEDD levodopa (mg) n.a. 235288 n.a. 445252
LEDD total dose (mg) n.a. 406 423 n.a. 729329
ISCED¼ International Standard Classification of Education,NART¼National Adult ReadingTest,CAMCOG¼ the cognitive part of the Cambridge
Examination for Mental Disorders of the Elderly, H&Ymodified¼modified version of the Hoehn and Yahr rating scale,UPDRS-III¼motor part of
the Unified Parkinson’s Disease Rating Scale, LEDD¼ levodopa equivalent daily dose, DA¼dopamine agonist; n.a.¼ not applicable.
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was not distorted. Mean relative power for each ROI was used in
the statistical analysis. Fast Fourier transformation was separately
applied for every subject on the three epochs in the previously
mentioned frequency bands. Results of the three epochs were
averaged for each subject. Reported spectral power values are all
relative.
Statistical analysis
Differences between Parkinson’s disease patients and controls in
the distribution of sex and education level were analysed by means
of chi-square tests. All analyses with regard to group differences in
age, pre-morbid IQ and CAMCOG scores were performed by
means of univariate analysis of variance (ANOVA). To increase
statistical power we attempted to normalize spectral power
parameters by means of a transformation that is considered to
be superior to other transformations when it comes to normal-
izing relative power in healthy controls (Gasser et al., 1982);
log[x/(1 x)]. Unfortunately 10 out of 60 regional spectral power
measures could not be sufficiently normalized in all groups by
means of this transformation to pass Kolmogorov–Smirnov tests
of normality. However, in the current study, we made use of
ANCOVA testing with repeated measures. ANCOVA testing is
usually not seriously confounded when the repeated measure
(relative power in a ROI) does not follow the normal distribution
in a limited number of levels (ROIs). More importantly, in our
post hoc analyses of regional spectral power we made use of linear
regression. This technique is rather robust when it comes to
violations of the assumption of normality as long as there are
(roughly) more than 10 observations and no substantial non-
normality that leads to outliers in the X–Y data. In that case
skewed distributions, light-tailedness as well as heavy-tailedness
have little effect on linear regression statistics. As our smallest
group still contains 18 observations per parameter and relative
power usually does not result in extreme outliers we chose, in the
interest of uniformity, to report parametric analyses of log-
transformed power values only.
Since our initial exploratory analyses even showed abnormal
spectral power in de novo Parkinson’s disease patients, we chose to
first compare spectral power in controls with de novo Parkinson’s
disease patients to show the effect of disease (experiment A) and,
subsequently, to perform analyses of the relation of spectral power
to disease duration, disease stage, disease severity and dose of
dopaminomimetics within the whole group of Parkinson’s disease
patients (experiment B). The acute effects of levodopa adminis-
tration (comparison of ‘ON’ and ‘OFF’ states) were analysed in
levodopa-treated Parkinson’s disease patients (experiment C).
Principal component analysis (PCA) was used in all subjects to
reduce the number of cognitive parameters to be used in the
assessment of the relation of spectral power with cognitive
performance (experiment D). Subsequent analyses were limited
to de novo patients, to exclude confounding effects of medication
on task performance. Relations between cognitive performance
and spectral power were only analysed for cognitive components,
frequency bands and ROIs that showed differences between
de novo Parkinson’s disease patients and controls. This approach
further reduces the number of analyses, in this way reducing the
likelihood of type-I statistical errors. All analyses were performed
at a significance level of 0.05 (two-tailed) using the SPSS 14.0.2
software package (SPSS Inc., Chicago, IL, USA). Partial eta
squared (Z2) was calculated when performing ANCOVA.
Coefficients for relevant determinants when performing regression
analysis were standardized and subsequently squared (b2). Both Z2
as well as b2 represent the proportion of the total variability in the
dependent variable (relative power) that is accounted for by the
relevant determinant, when controlling for all other covariants/
determinants in the ANCOVA model or regression equation.
Throughout the paper, Z2 and b2 are expressed as a percentage of
the total variance.
Experiment A: For each frequency band, ANCOVA with
repeated measures was performed, using Greenhouse–Geiser
corrected P-values for interaction effects. The repeated measures
factor had 10 levels (relative power in the frontal, central,
temporal, parietal and occipital ROI for the left and right side of
the brain). The between-subjects factor had two levels (de novo
Parkinson’s disease patients and controls; effect of disease).
Relevant confounders were used as covariates. In case of a
significant main effect for group or an interaction effect of group
with ROI, subsequent post hoc analyses with regard to regional
differences in spectral power between de novo Parkinson’s disease
patients (N¼ 18) and controls (N¼ 21) were performed by means
of linear regression using each of the regional spectral power
measures as dependent and group membership (effect of disease)
and any relevant confounders as determinants.
Experiment B: Analyses of the relation of spectral power with
disease parameters in Parkinson’s disease patients (N¼ 70)
involved a separate ANCOVA with repeated measures for each
frequency band, using Greenhouse–Geiser corrected P-values for
interaction effects. The repeated measures factor was identical to
experiment A. Relevant confounders as well as disease duration
(effect of disease duration), modified Hoehn and Yahr stage in the
‘OFF’ medication phase (effect of disease stage), UPDRS motor
score in the ‘OFF’ medication phase (effect of disease severity)
or LEDD (effect of dose of dopaminomimetics) were used as
covariates. In case of a significant main effect for a disease
parameter or an interaction effect for the disease parameter with
ROI, subsequent post hoc analyses of the relation of regional spectral
power with disease parameters were performed by means of linear
regression using each of the regional spectral power measures in the
‘OFF’ medication phase as dependent and either disease duration,
modified Hoehn and Yahr stage in the ‘OFF’ medication phase,
UPDRS motor score in the ‘OFF’ medication phase or LEDD as
well as any relevant confounders as determinants. Relations of total
Fig. 1 Clustering of MEG sensors into regions of interest above
the major cortical areas. Midline sensors (depicted in black) have
been excluded from power spectral analysis. R¼ right, L¼ left,
F¼ frontal, C¼ central, T¼ temporal, P¼parietal, O¼ occipital.
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tremor score (UPDRS motor sub-score) with spectral power were
explored using Spearman’s non-parametric correlation analysis, as
exploratory scatterplots showed severe non-normality with outliers
in the X–Y data.
Experiment C: Analyses to determine the immediate modula-
tory effect of dopaminomimetic drugs on power values (effect of
acute dopaminomimetic challenge) in levodopa-treated
Parkinson’s disease patients (N¼ 37) were performed by means
of Student’s paired t-tests.
Experiment D: Analyses to reduce the number of cognitive
parameters were performed by means of PCA with varimax
rotation and Kaiser normalization in all subjects (N¼ 91) on the
following 11 variables: span length (spatial span), between search
errors (spatial working memory), strategy (spatial working
memory), mean initial thinking time on five move problems
(stockings of Cambridge), mean subsequent thinking time on five
moves (stockings of Cambridge), problems solved in five moves
(stockings of Cambridge) stages completed (intra-dimensional/
extra-dimensional shift), adjusted total errors (intra-dimensional/
extra-dimensional shift), redundancy of the second order
(Vienna perseveration), analytical IQ (Raven’s standard progres-
sive matrices) and category fluency (CAMCOG). All analyses
with regard to differences in cognitive performance between
de novo Parkinson’s disease patients (N¼ 18) and controls
(N¼ 21) were analysed by means of linear regression using each
of the cognitive components from the PCA as dependent and
group membership (effect of disease) and any relevant confoun-
ders as determinants. All analyses of the relation of spectral power
with cognitive performance in Parkinson’s disease patients
involved a separate ANCOVA with repeated measures for each
frequency band, using Greenhouse–Geiser corrected P-values for
interaction effects. The repeated measures factor was identical to
experiment A. Relevant confounders as well as one of the
cognitive components from the PCA (relation with cognitive
function) were used as covariates. In case of a significant
main effect for a cognitive parameter or an interaction effect for
a cognitive parameter with ROI, subsequent post hoc analyses
of the relation of cognitive performance with regional spectral
power involved linear regression using each of the regional
spectral power measures in the ‘OFF’ medication phase as
dependent and a cognitive component from the principal
component analysis (relation with cognitive function) and any
relevant confounders as determinants.
Results
Subject characteristics and confounders
There were no differences in the distribution of sex or
education level over the various groups (controls, all
Parkinson’s disease patients, de novo Parkinson’s disease
patients, levodopa-treated Parkinson’s disease patients).
There were no significant differences in age, pre-morbid
IQ (NART) or global cognitive function (CAMCOG)
between groups. Since age is known to be a modifier of
spectral power (Van Sweden et al., 1999), it was nonetheless
added as a covariate/determinant in all analyses of spectral
power in experiments A, B and D, as was sex. Since age and
pre-morbid IQ are known to be modifiers of cognitive
performance, they were added as determinant in analyses of
differences in cognitive performance between patients and
controls in experiment D, as was sex.
Experiment A: effect of disease
ANCOVA testing showed de novo Parkinson’s disease
patients to have higher power than controls in the theta
(P¼ 0.004, Z2¼ 21.7%) and low alpha (P50.001,
Z2¼ 35.4%) frequency bands and lower power in the beta
(P50.001, Z2¼ 32.4%) and gamma (P50.001,
Z2¼ 29.8%) frequency bands. No differences in spectral
power between controls and de novo Parkinson’s disease
patients were found in the delta and high alpha frequency
bands. An interaction for group with ROI was observed in
the low alpha (P¼ .007, Z2¼ 11.0%), high alpha
(P¼ 0.036, Z2¼ 7.7%) and beta (P¼ 0.014, Z2¼ 10.7%)
frequency bands. Post hoc regression analysis showed
de novo Parkinson’s disease patients to have higher power
than controls in all 10 cortical areas in the theta and low
alpha band. Beta power was significantly lower in de novo
Parkinson’s disease patients when compared to controls in
all but the frontal ROIs. In the gamma band, lower power
was found in all but the right occipital ROI, when
comparing de novo Parkinson’s disease patients to controls.
No differences in regional spectral power between
controls and de novo Parkinson’s disease patients were
found in the delta and high alpha frequency bands.
For means and standard deviations of regional relative
spectral power values and accompanying statistics see
Table 2, for a graphical depiction see Fig. 2. The overall
changes in relative power can be appreciated from a line
chart showing global relative spectral power density for de
novo Parkinson’s disease patients, age-matched controls as
well as the full group of Parkinson’s disease patients
(Fig. 3).
Experiment B: effect of disease duration,
disease stage, disease severity and effect
of dose of dopaminomimetics
ANCOVA testing revealed no main effects of disease dura-
tion in any frequency band. An interaction of disease dura-
tion with ROI was observed in the low alpha (P¼ 0.023,
Z2¼ 4.4%) frequency band. Subsequent post hoc regression
analyses showed an effect of disease duration on regional
spectral power in two ROIs in the low alpha band: relative
spectral power decreased with increasing disease duration
in both the right temporal (b¼0.020, 95%CI¼0.038 to
0.003, P¼ 0.026, b2¼ 7.12%) and right occipital
(b¼0.023, 95% CI¼0.041 to 0.004, P¼ 0.016,
b2¼ 8.18%) ROIs (Fig. 4A and B). ANCOVA testing
showed no main or interaction effects of disease stage, as
assessed by the modified Hoehn and Yahr scale, or disease
severity, quantified using the total score of the motor
section of the UPDRS, on spectral power values in
any frequency band. Furthermore, total tremor score
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Table 2 Means SDs and accompanying statistics of relative spectral power values in the six frequency bands for controls
and de novo Parkinson’s disease patients in experiment A
Frequency band Area Controls
(N¼ 21)
De novo Parkinson’s
disease patients
(N¼18)
Statistic
b 95%CI P b2
Delta L frontal 0.3510.101 0.314 0.129 0.061 0.212 to 0.090 0.416 1.79
(0.5^4Hz) R frontal 0.338 0.099 0.314 0.140 0.036 0.192 to 0.119 0.639 0.59
L central 0.2110.073 0.198 0.067 0.024 0.141 to 0.104 0.711 0.36
R central 0.198 0.066 0.190 0.074 0.014 0.135 to 0.108 0.821 0.13
L temporal 0.318 0.076 0.2710.085 0.104 0.217 to 0.010 0.072 8.82
R temporal 0.310 0.089 0.283 0.122 0.064 0.208 to 0.079 0.368 2.28
L parietal 0.166 0.067 0.1470.063 0.066 0.220 to 0.088 0.389 2.16
R parietal 0.168 0.070 0.143 0.060 0.086 0.241 to 0.068 0.263 3.65
L occipital 0.175 0.076 0.185 0.104 0.006 0.168 to 0.179 0.949 0.01
R occipital 0.178 0.066 0.1870.100 0.006 0.167 to 0.156 0.941 0.02
Theta L frontal 0.138 0.029 0.1870.064 0.136 0.033 to 0.239 0.011 16.24
(4^8Hz) R frontal 0.138 0.032 0.186 0.055 0.135 0.042 to 0.229 0.006 17.98
L central 0.1310.033 0.170 0.055 0.115 0.003 to 0.227 0.044 10.98
R central 0.123 0.031 0.1610.050 0.116 0.009 to 0.223 0.035 11.08
L temporal 0.120 0.026 0.1810.071 0.179 0.079 to 0.279 0.001 25.20
R temporal 0.124 0.032 0.168 0.066 0.129 0.026 to 0.232 0.016 13.76
L parietal 0.109 0.032 0.156 0.065 0.152 0.033 to 0.272 0.014 14.98
R parietal 0.100 0.025 0.152 0.065 0.164 0.044 to 0.285 0.009 16.24
L occipital 0.102 0.034 0.1670.082 0.199 0.077 to 0.321 0.002 19.71
R occipital 0.105 0.033 0.159 0.068 0.177 0.064 to 0.290 0.003 19.62
Low alpha L frontal 0.0770.041 0.116 0.049 0.187 0.048 to 0.326 0.010 16.81
(8^10Hz) R frontal 0.0710.020 0.1110.057 0.170 0.027 to 0.312 0.021 14.44
L central 0.096 0.059 0.159 0.061 0.267 0.122 to 0.413 0.001 26.83
R central 0.092 0.039 0.1710.075 0.304 0.167 to 0.441 50.001 34.57
L temporal 0.112 0.072 0.215 0.078 0.365 0.209 to 0.521 50.001 38.31
R temporal 0.113 0.060 0.223 0.096 0.356 0.187 to 0.526 50.001 33.53
L parietal 0.1410.101 0.2770.118 0.400 0.214 to 0.585 50.001 33.29
R parietal 0.144 0.098 0.2970.123 0.436 0.244 to 0.627 50.001 35.40
L occipital 0.158 0.105 0.2770.118 0.347 0.154 to 0.539 0.001 26.73
R occipital 0.159 0.107 0.2770.123 0.337 0.140 to 0.533 0.001 24.80
High alpha L frontal 0.0770.025 0.082 0.029 0.022 0.084 to 0.128 0.678 0.46
(10^13Hz) R frontal 0.084 0.026 0.080 0.032 0.052 0.177 to 0.073 0.401 1.85
L central 0.110 0.035 0.116 0.036 0.027 0.078 to 0.131 0.610 0.76
R central 0.122 0.109 0.112 0.038 0.045 0.154 to 0.063 0.403 1.98
L temporal 0.1170.035 0.103 0.101 0.064 0.172 to 0.043 0.230 3.96
R temporal 0.125 0.037 0.1010.037 0.105 0.214 to 0.003 0.057 9.55
L parietal 0.173 0.068 0.155 0.075 0.064 0.209 to 0.080 0.373 2.25
R parietal 0.1770.062 0.1470.062 0.093 0.225 to 0.038 0.159 5.34
L occipital 0.178 0.084 0.130 0.057 0.143 0.287 to 0.000 0.050 9.86
R occipital 0.1710.086 0.128 0.055 0.124 0.265 to 0.018 0.086 7.34
Beta L frontal 0.283 0.089 0.2470.074 0.091 0.218 to 0.035 0.152 5.76
(13^30Hz) R frontal 0.294 0.089 0.256 0.084 0.111 0.263 to 0.040 0.146 5.76
L central 0.380 0.094 0.310 0.078 0.133 0.240 to 0.026 0.016 14.06
R central 0.3910.098 0.3170.083 0.141 0.249 to 0.032 0.013 14.52
L temporal 0.264 0.058 0.188 0.057 0.191 0.289 to 0.093 50.001 29.70
R temporal 0.268 0.069 0.185 0.061 0.212 0.328 to 0.097 0.001 27.87
L parietal 0.358 0.073 0.238 0.078 0.250 0.356 to 0.144 50.001 34.93
R parietal 0.358 0.078 0.232 0.080 0.269 0.380 to 0.157 50.001 40.96
L occipital 0.300 0.073 0.193 0.057 0.253 0.361 to 0.144 50.001 38.56
R occipital 0.305 0.071 0.193 0.055 0.262 0.361 to 0.163 50.001 44.49
Gamma L frontal 0.075 0.028 0.053 0.017 0.149 0.259 to 0.039 0.009 17.98
(30^48Hz) R frontal 0.075 0.028 0.053 0.021 0.181 0.318 to 0.045 0.011 17.39
L central 0.0710.026 0.046 0.016 0.186 0.294 to 0.079 0.001 24.70
R central 0.074 0.024 0.0470.018 0.202 0.311 to 0.092 0.001 27.56
L temporal 0.069 0.032 0.050 0.015 0.219 0.344 to 0.094 0.001 25.50
R temporal 0.060 0.026 0.040 0.020 0.206 0.350 to 0.061 0.007 19.36
L parietal 0.053 0.021 0.029 0.014 0.283 0.431 to 0.134 50.001 27.98
R parietal 0.054 0.020 0.029 0.015 0.284 0.425 to 0.143 50.001 31.25
L occipital 0.086 0.065 0.049 0.029 0.242 0.468 to 0.016 0.037 11.97
R occipital 0.083 0.052 0.055 0.034 0.200 0.408 to 0.007 0.057 10.11
Significant differences between de novo Parkinson’s disease patients and controls are indicated in bold. L¼ left, R¼ right; b¼ regression
coefficient, 95% CI¼ 95% confidence interval of b, P¼probability of finding the present or a more extreme result, assuming the null
hypothesis is true, b2¼ explained variance (%).
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(UPDRS motor sub-score) and spectral power were
unrelated, as determined using Spearman’s non-parametric
correlation analysis. Lastly, no main or interaction effects
were found between LEDD and spectral power.
Experiment C: effect of an acute
dopaminomimetic challenge
When comparing the ‘ON’ state with the ‘OFF’ state in
levodopa-treated patients, we found only a slight modula-
tory effect of levodopa administration on spectral power.
Changes were limited to decreases of relative power in right
frontal theta (P¼ 0.048), left occipital beta (P¼ 0.015) and
left temporal gamma (P¼ 0.003), and an increase in right
parietal gamma power (P¼ 0.048) after intake of
dopaminomimetics.
Experiment D: relation with
cognitive function
PCA with varimax rotation in the complete group of
subjects (N¼ 91) yielded four components. Based on the
factor loadings of the various tasks on the individual
components, these could in our opinion best be attributed
to four cognitive (executive) functions: strategy/analysis,
set-shifting, planning/spatial memory and perseveration
(Table 3). Subsequent linear regression analyses showed
de novo Parkinson’s disease patients to have a lower
capacity for planning/spatial memory (b¼ 0.404, 95%
CI¼ 0.038 to 0.770, P¼ 0.031, b2¼ 11.76%) and higher
perseveration (b¼0.705, 95% CI¼1.335 to 0.075,
P¼ 0.029, b2¼ 11.76%) compared to controls. No signifi-
cant differences in performance between de novo
Parkinson’s disease patients and controls were found with
regard to strategy/analysis or set-shifting. In the group of
de novo Parkinson’s disease patients, ANCOVA testing
revealed a main effect of perseveration on spectral power
(P¼ 0.049, Z2¼ 24.8%). Subsequent post hoc regression
analyses showed increased perseveration in de novo
Parkinson’s disease patients to be associated with higher
low alpha power in left central (b¼0.086, 95%
CI¼0.162 to 0.010, P¼ 0.030, b2¼ 27.56%), right
central (b¼0.102, 95% CI¼0.193 to 0.010,
P¼ 0.031 b2¼ 27.66%), left parietal (b¼0.108, 95%
CI¼0.209 to 0.007, P¼ 0.038, b2¼ 24.70%) and right
parietal (b¼0.124, 95% CI¼0.230 to 0.018,
P¼ 0.025, b2¼ 27.77%) ROIs (Fig. 5). ANCOVA testing
did not show any effects of planning/working memory on
spectral power.
Discussion
In a previous MEG study using similar methodology to the
current, we compared resting-state oscillatory brain activity
in groups of demented (N¼ 13) and non-demented
(N¼ 13) Parkinson’s disease patients matched with regard
to age, sex and disease duration, as well as in 13 age- and
sex-matched controls (Bosboom et al., 2006). This study
showed extensive changes in oscillatory brain activity in
non-demented Parkinson’s disease patients at moderately
advanced stages of disease relative to controls, which
included an increase in theta power over all but the frontal
ROIs as well as decreases in mainly posterior beta and
centroparietal gamma power. When comparing demented
to non-demented Parkinson’s disease patients, the most
conspicuous changes were a diffuse increase in delta power
and a diffuse decrease in alpha power in the demented
patients. Furthermore, in the demented Parkinson’s disease
patients, we observed an additional increase in theta power
restricted to the left frontal, bilateral central and right
parietal ROIs as well as further widespread decreases in beta
power and a decrease in frontal gamma power. Since our
previous study involved only moderately advanced, non-
demented Parkinson’s disease patients who had already
been on dopaminomimetic treatment for many years, it was
at that point unclear whether slowing of resting-state
oscillatory brain activity is an early stage characteristic of
Parkinson’s disease or a phenomenon that develops over
the course of the disease, as a result of disease progression
and/or (prolonged) exposure to dopaminergic agents.
Fig. 2 Schematic view of differences in relative spectral power in
experiment A in the various frequency bands and regions of
interest between de novo Parkinson’s disease patients (N¼18) and
age-matched controls (N¼ 21).Colour indicates direction of effect,
colour intensity signifies magnitude of effect (variance explained by
group membership in the regression equation, which further
included sex and age as determinants). R¼ right, L¼ left,
F¼ frontal, C¼ central, T¼ temporal, P¼parietal, O¼ occipital,
n.s.¼ not significant, b2¼ explained variance (%).
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Fig. 3 Line chart showing relative spectral power averaged over all MEG sensors for de novo Parkinson’s disease patients (N¼18), controls
(N¼ 21) and the full group of Parkinson’s disease patients (N¼ 70) in the 0.5 to 48Hz frequency range. Note the differences in frequency
distribution between controls and de novo Parkinson’s disease patients as well as the similarities between de novo Parkinson’s disease
patients and the full group of Parkinson’s disease patients.
Fig. 4 Scatterplots showing relative spectral power in the low alpha band in the right temporal (A) and right occipital (B) regions of
interest set out against disease duration in all Parkinson’s disease patients (N¼ 70). In the post hoc regression analyses, which further
included age and sex as determinants, disease duration explained 7.12% of the variance of spectral power in the right temporal region of
interest and 8.18% of the variance in the right occipital region of interest.
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In the present whole-head MEG study, de novo, untreated
Parkinson’s disease patients showed considerable slowing of
resting-state oscillatory brain activity compared to healthy
controls, consisting of a widespread increase in theta and
low alpha power, a slight change in the cortical distribution
of high alpha power, as well as a loss of beta power over all
but the frontal ROIs and a loss of gamma power over all
but one ROI. Based on the results of the analysis in our
whole group of Parkinson’s disease patients, these changes
in relative power values appear to be (largely) unrelated to
disease duration, disease stage, disease severity and LEDD.
Interestingly, power values in levodopa-treated patients
were hardly modulated by an acute dopaminergic challenge.
In addition, we found indications that an aspect of
cognitive dysfunction in de novo Parkinson’s disease
patients is associated with increased low alpha power in
central and parietal ROIs.
Contrary to our own results, most studies have been
unable to show evidence of (pronounced) slowing of
resting-state brain activity in non-demented Parkinson’s
disease patients. Several factors might account for this
discrepancy. First, we used MEG instead of EEG in the
current study. EEG measures the electrical derivative of
underlying brain activity, which is based on the difference
in potentials between an EEG electrode and a reference
electrode. This signal is severely influenced by the electric
conductivity of intermediate structures, especially the skull.
MEG measures absolute magnetic flux, the magnetic
derivative of electrical brain activity. Contrary to electricity,
the magnetic fields measured with MEG pass through
intermediate structures almost undisturbed. In addition,
MEG is a reference-free technique that employs a higher
sensor density than conventional EEG; our study uses 141
sensors as opposed to a maximum of 20 EEG electrodes in
previous EEG studies. As a consequence of the resulting
superior spatial resolution and signal-to-noise ratio of MEG
compared to EEG, it might very well pick up changes of
oscillatory brain activity not evident in the EEG signal.
Another factor is that we used log-transformed relative
power combined with advanced statistical techniques in the
current study, which can significantly increase statistical
power, especially in MEG studies.
The question may arise whether the eyes-closed resting
state is the most effective condition for demonstrating
changes in oscillatory brain activity in Parkinson’s disease
and, especially, their relation with indices of cognitive and
motor function. For instance, the results of an EEG study
using coherence and a visuomotor tracking task suggest
that task-induced EEG changes might increase the dis-
crimination between controls and Parkinson’s disease
Table 3 Factor loadings of the individual tests on the four components extracted in the principal component analysis with
varimax rotation in all subjects (N¼ 91) in experiment C
Cognitive test variable Component
1 2 3 4
SSP span length 0.705 0.020 0.218 0.005
SWM between errors 0.880 0.072 0.062 0.044
SWM strategy 0.826 0.110 0.019 0.031
SOC mean initial thinking time (five moves) 0.066 0.160 0.863 0.011
SOC mean subsequent thinking time (five moves) 0.289 0.388 0.619 0.065
SOC problems solved in minimum moves 0.481 0.069 0.160 0.572
IED total errors (adjusted) 0.120 0.955 0.023 0.123
IED stages completed 0.105 0.965 0.023 0.047
Vienna Raven SPM 0.519 0.321 0.236 0.225
Vienna perseveration 0.109 0.070 0.078 0.886
Category fluency 0.423 0.178 0.097 0.343
The highest factor loading per test has been indicated in bold. Component 1: strategy/analysis; 2: set-shifting; 3: planning/spatial memory;
4: perseveration. SSP¼ spatial span, SWM¼ spatial working memory, SOC¼ stockings of Cambridge, IED¼ intra/extra-dimensional shift,
SPM¼ standard progressive matrices.
Fig. 5 Schematic view showing the location in MEG sensor space
and magnitude of associations between relative spectral power in
the low alpha band and the degree of cognitive perseveration in
de novo Parkinson’s disease patients (N¼18). Colour intensity sig-
nifies magnitude of effect (variance explained by cognitive perse-
veration in the regression equation, which further included sex and
age as determinants). R¼ right, L¼ left, F¼ frontal, C¼ central,
T¼ temporal, P¼parietal, O¼ occipital, n.s.¼ not significant,
b2¼ explained variance (%).
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patients (Cassidy et al., 2001). A number of recent fMRI
studies, however, have shown that the resting state is a far
more stable and active condition than has often been
assumed (Gusnard and Raichle, 2001). The resting state is
characterized by the activation of a ‘default’ network, which
consists of frontal, posterior cingulate, parietal and medial
temporal areas (Laufs et al., 2003). Using MEG, abnorm-
alities of resting-state network activity have been demon-
strated in demented and non-demented Parkinson’s disease
patients (Bosboom et al., 2006), multiple sclerosis (Cover
et al., 2006) and Alzheimer’s disease (Stam et al., 2006).
The results of the present study further strengthen the idea
that a simple resting-state condition is sufficient to
demonstrate widespread changes in oscillatory brain
dynamics in diseases of the brain. Obviously, this does
not imply that the use of specific motor and cognitive tasks,
aimed at activating brain areas assumed to be involved
in Parkinson’s disease, is not useful at all. However,
brain pathology may be associated with either abnormally
high or abnormally low task-related activation, thus
seriously complicating the interpretation of the results of
task-related data.
Parkinsonian tremor generally has a frequency in the
theta range (4–7 Hz). Timmermann and co-workers
reported coherence between tremor, measured with EMG,
and several MEG oscillatory rhythms in the contralateral
motor cortex (Timmermann et al., 2003). In theory, these
area-specific coherent oscillations could influence spectral
power values. Since the observed theta power changes in
the present study are widely distributed, these differences
can hardly be explained by MEG oscillatory activity that is
coherent with tremor. Alternatively, tremor could diffusely
influence the MEG signal in a direct way through move-
ment artefacts influencing power in the theta band.
However, in our patients, UPDRS tremor scores did not
correlate with MEG activity in any frequency band, most
notably not in the theta band. Lastly, epochs were carefully
selected for the absence of visible tremor. Taken together,
we believe that it is highly unlikely that tremor could
account for the differences between patients and controls
observed in the theta band.
The use of dopaminergic medication is theoretically a
confounding factor when performing analyses in controls
and untreated Parkinson’s disease patients on the one hand
and the whole group of Parkinson’s disease patients,
including those dopaminomimetically treated, on the
other. To minimize the potential effects of antiparkinsonian
medication on the results of this study, MEG recordings in
dopaminomimetically treated Parkinson’s disease patients
were obtained in a practically defined ‘OFF’ state, i.e. at
least 9 h after the last dose of medication. In spite of this,
effects of dopaminergic treatment may not have been fully
abolished in this way, in particular in patients on dopamine
agonists with a long half-life. Although these effects for
obvious reasons have not influenced our finding of
substantial power differences between controls and
untreated de novo patients, they may have masked a
stronger or more widespread correlation between disease
duration and spectral power changes. On the other hand,
the lack of major differences between ‘ON’ and ‘OFF’
registrations would argue against a significant confounding
influence of dopaminergic treatment.
We chose to use relative power in the present study. As
opposed to absolute power, relative power is not influenced
by the distance between the MEG sensor and underlying
neural populations. This distance is highly variable over
individual subjects due to factors such as skull thickness
and head position within the MEG helmet. Using relative
power rather than absolute power results in a lower
variance of power values within subject groups, which
will substantially increase statistical power when making
group comparisons. A drawback of using relative power is
that it can complicate interpretation when making group
comparisons. Relative power in a specific frequency band is
influenced by the power in other bands; therefore group
differences in relative power in a specific frequency band
might not result from changes in absolute power in that
frequency band per se, but rather from changes in absolute
power in other frequency bands. Differences in relative
power between groups within a specific frequency band
should therefore always be interpreted with that proviso
in mind.
In the present study, we adopted a pragmatic approach
with regard to our spatial locations of interest, restricting
the analyses to the actually recorded signal of the MEG
sensors (‘sensor space’) and clustering the MEG sensors
into 10 cortical ROIs based on their approximate position
relative to the major cortical brain regions. An alternative
method is the use of source modelling techniques such as
synthetic aperture magnetometry, enabling investigation of
the distribution of reconstructed sources over the various
cortical regions (‘source space’). However, no unique way
exists to reconstruct the sources, and results from different
techniques can show significant discrepancies. As a
consequence of our approach, changes observed in regions
of sensor space cannot be directly interpreted as reflecting
physiological changes in the brain regions underlying the
sensors. Even so, differences between controls and de novo
Parkinson’s disease patients in the present study were
diffusely distributed over the 10 ROIs. Therefore, it is
unlikely that our results were significantly influenced by
using sensor space rather than source space.
The present study is the first to report widespread
slowing of resting-state brain activity in de novo, untreated
Parkinson’s disease patients. Considering the fact that
we were able to detect these changes in the earliest
clinical stages, it is tempting to speculate that the
onset of these alterations actually lies in the preclinical
stages of Parkinson’s disease, which precede the onset of
the classical motor signs. In the preclinical stages (I and II)
and the earliest clinical stage (III) of the Braak neuro-
pathological staging system (Braak et al., 2003),
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Parkinson’s disease-specific neuropathological changes are
most prevalent in the brainstem, including dopaminergic,
serotonergic and noradrenergic structures. To a lesser
extent, also the forebrain cholinergic system is affected.
The alterations of oscillatory cortical activity demonstrated
in the present study may therefore find their origin in
degeneration of ascending corticopetal projection systems
originating in the brainstem.
The neuropathological hallmark of clinically non-demen-
ted Parkinson’s disease is a progressive deterioration of the
nigrostriatal dopaminergic system. In the present study,
changes in resting-state oscillatory brain dynamics in
de novo Parkinson’s disease patients remained relatively
constant with progression of subjective disease duration
from 0 up to 13 years, modified Hoehn and Yahr stage
from I up to III and UPDRS motor score from 6 up to 35.
These findings strongly argue against a (major) involvement
of the dopaminergic system in the observed changes in
oscillatory brain dynamics in Parkinson’s disease. Also,
some of the other findings in our study argue against the
dopaminergic system as a major player in early stage
alterations of oscillatory brain activity in Parkinson’s
disease. Resting-state oscillatory activity was hardly modu-
lated by dopaminomimetic treatment, as acute administra-
tion had only minimal effects on spectral power, whereas
LEDD was not associated with spectral power values.
Literature data on the effect of changes in dopaminergic
neurotransmission on resting-state oscillatory brain activity
in Parkinson’s disease patients are scarce. As of yet, we are
aware of a single EEG study utilizing frequency analysis, in
which an increase in spectral power after treatment with
levodopa was reported. The increase was localized to the
left occipital lobe and was present over all frequency bands
(Yaar and Shapiro, 1983). In this study, 25 parkinsonian
patients (of which disease duration, stage and severity as
well as use of concomitant maintenance medication is not
reported) were examined prior to and 14 to 30 days after
the initiation of levodopa therapy. Maintenance levels of
levodopa (without a decarboxylase inhibitor) therapy
reached 3 to 5 g/day. This is equivalent to roughly 750 to
1250 mg/day of levodopa with a peripheral decarboxylase
inhibitor. Clearly, this is a much higher dose than the
average 445 mg in our sample, which suggests that patients
were at a more advanced stage of disease and therefore hard
to compare with the present population of Parkinson’s
disease patients. It might be argued that with further
increasing dopaminergic losses, effects of exogenous
levodopa become stronger. This assumption should be
addressed in future studies in more advanced Parkinson’s
disease patients.
As argued earlier, a role for the dopaminergic system in
early changes in resting-state oscillatory brain dynamics in
Parkinson’s disease seems rather unlikely. A more likely
alternative candidate to explain these changes in spectral
power in Parkinson’s disease is the noradrenergic system,
arising in the brainstem locus coeruleus. In animal studies,
stimulation of the locus coeruleus induces a shift in the
electroencephalogram towards higher frequencies (Berridge
and Foote, 1991) and conversely, suppression of noradre-
nergic neurotransmission induces slow wave activity
(Berridge et al., 1993). Another option is the serotonergic
system originating in the dorsal raphe nuclei. Promotion of
serotonergic activity, either by stimulation of the dorsal
raphe nucleus or injection of serotonergic agonists into the
cerebral cortex, is associated with the emergence of fast
frequency cortical EEG activity in animal studies
(Vanderwolf and Baker, 1986). On the other hand, lesions
of this brainstem nucleus and therefore loss of the
ascending serotonergic cortical projections have been
found to result in a reduction or inhibition of this cortical
activation (Vanderwolf et al., 1990; Peck and Vanderwolf,
1991).
The cholinergic system also has a modulatory influence
on cortical activity as evidenced by several animal as well as
human studies (De´ta´ri and Vanderwolf, 1987; Buzsaki et al.,
1988). After cholinergic stimulation, a decrease of slow,
mainly delta activity and an increase of fast EEG back-
ground activity has been found. In contrast, degeneration
or lesioning of the cholinergic cortical projections from the
basal nucleus of Meynert, with a corresponding loss of
cortical cholinergic activity, as well as a blockade of
postsynaptic cortical muscarinic receptors, are associated
with an increase in slow, mainly delta activity (Riekkinen
et al., 1991; Ray and Jackson, 1991; Soininen et al., 1992;
Ebert and Kirch, 1998; Dringenberg et al., 2000; Osipova
et al., 2003; Ricceri et al., 2004). As lesions in the
cholinergic system primarily result in an increase in delta
activity, an observation not found in the present study
in non-demented Parkinson’s disease patients, and the
cholinergic nucleus basalis appears only to be mildly
affected in the earliest clinical stages of Parkinson’s disease
(Braak et al., 2003), we think this system is not so much
involved in altered oscillatory brain dynamics in non-
demented Parkinson’s disease patients. Instead, cholinergic
deficits appear to come into play in demented Parkinson’s
disease patients as evidenced by the increases in delta power
in these patients (Soikkeli et al., 1991; Neufeld et al., 1994;
Tanaka et al., 2000; Bosboom et al., 2006).
In our untreated, de novo Parkinson’s disease patients,
worse performance on perseveration-related tasks was
associated with increased low alpha in central and parietal
ROIs. Alpha oscillations are thought to play an important
role in attentional processes. Oscillatory alpha activity
probably indicates that attention is actively suppressing
cortical activity related to distracters as a part of
the process of focusing attention on important targets
(Ward, 2003). For example, alpha power increases with
memory load in the Sternberg memory-scanning task,
reflecting an increase in the need to suppress distraction
(Jensen et al., 2002). Moreover, when attention is directed
internally towards mental imagery, alpha power at
attention-relevant scalp sites is greater than during
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externally directed, information-intake tasks, reflecting
suppression of external input during the imagery task
(Cooper et al., 2003). Also in this study, alpha power
increased with increasing external task load, reflecting the
need to suppress competing information sources.
Especially lower alpha synchronization (in the range of
about 6–10 Hz) is thought to reflect general task demands
and attentional processes, and is topographically wide-
spread over the entire scalp (Klimesch, 1999). Although
highly speculative, it may be that increased low alpha
oscillations in central and parietal regions in our de novo
Parkinson’s disease patients are a sign of a pathologically
high level of attention. This might cause an inability to
switch behavioural programmes resulting in increased
perseveration. This notion is further supported by the fact
that the increase in low alpha power in the present study
also involves the parietal lobe that has a well-established
role in attention, especially with regard to attentional-
shifting (Posner and Petersen, 1990). However, we cannot
exclude the possibility that the associations found are
produced by a single alpha source, which synchronizes
activity in all the four ROIs and at the same time is
associated with cognitive perseveration. Obviously, the
current results do not warrant a definitive judgement in
this matter.
In conclusion, our results demonstrate that a widespread
slowing of resting-state oscillatory brain activity is a very
early and probably preclinical feature of Parkinson’s
disease, largely unrelated to disease stage, duration and
severity, and hardly modulated by dopaminomimetic
treatment. We propose that these early changes in resting-
state brain activity in Parkinson’s disease mainly result from
a degeneration of noradrenergic and/or serotonergic
corticopetal projections arising in the brainstem.
Longitudinal studies of resting-state brain activity in
Parkinson’s disease, including patients at more advanced
disease stages, are necessary to confirm that slowing
of resting-state oscillatory activity is indeed a stable feature
in Parkinson’s disease. Such studies may also clarify what
changes in the pattern of oscillatory brain activity mark
or even predict the onset of Parkinson’s disease-related
dementia.
Acknowledgements
The financial support of the Dutch Parkinson Foundation
(Parkinson Patie¨nten Vereniging) and the Dutch
Foundation for Brain Research (Nederlandse
Hersenstichting, grant no. 11F03(2)05) is gratefully
acknowledged. We would like to thank G. de Vos and
engineer J. Verbunt for technical assistance, M. M. Ponsen,
MD and A. Winogrodzka, MD, for clinical (UPDRS)
testing, J. Twisk, PhD, for statistical advice and E. M. van
Deventer for librarian assistance.
References
American Psychiatric Association. Diagnostic and statistical manual of
mental disorders DSM-IV-TR. Washington DC: American Psychiatric
Association; 2000.
Berridge CW, Foote SL. Effects of locus coeruleus activation on
electroencephalographic activity in neocortex and hippocampus.
J Neurosci 1991; 11: 3135–45.
Berridge CW, Page ME, Valentino RJ, Foote SL. Effects of locus coeruleus
inactivation on electroencephalographic activity in neocortex and
hippocampus. Neuroscience 1993; 55: 381–93.
Bosboom JLW, Stoffers D, Stam CJ, van Dijk BW, Verbunt J,
Berendse HW, et al. Resting-state oscillatory brain dynamics in
Parkinson’s disease: an MEG study. Clin Neurophysiol 2006; 117:
2521–31.
Braak H, Del Tredici K, Ru¨b U, de Vos RAI, Jansen Steur ENH, Braak E.
Staging of brain pathology related to sporadic Parkinson’s disease.
Neurobiol Aging 2003; 24: 197–211.
Bright P, Jaldow E, Kopelman MD. The National Adult Reading Test as a
measure of premorbid intelligence: a comparison with estimates derived
from demographic variables. J Int Neuropsychol Soc 2002; 8: 847–54.
Buzsaki G, Bickford RG, Ponomareff G, Thal LJ, Mandel R, Gage FH.
Nucleus basalis and thalamic control of neocortical activity in the freely
moving rat. J Neurosci 1988; 8: 4007–26.
Cassidy M, Brown P. Task-related EEG-EEG coherence depends on
dopaminergic activity in Parkinson’s disease. Neuroreport 2001; 12:
703–7.
Centraal Bureau voor Statistiek. Standaard onderwijsindeling SOI-2003.
Voorburg: CBS; 2003.
Cooper NR, Croft RJ, Dominey SJJ, Burgess AP, Gruzelier JH. Paradox
lost? Exploring the role of alpha oscillations during externally vs.
internally directed attention and the implications for idling and
inhibition hypotheses. Int J Psychophysiol 2003; 47: 65–74.
Cover KS, Vrenken H, Geurts JJG, van Oosten BW, Jelles B, Polman CH,
et al. Multiple sclerosis patients show a highly significant decrease in
alpha band interhemispheric synchronization measured using MEG.
Neuroimage 2006; 29: 783–8.
De´ta´ri L, Vanderwolf CH. Activity of identified cortically projecting and
other basal forebrain neurones during large slow waves and cortical
activation in anaesthetized rats. Brain Res 1987; 437: 1–8.
Dringenberg HC, Diavolitsis P, Noseworthy PA. Effect of tacrine on EEG
slowing in the rat: enhancement by concurrent monoamine therapy.
Neurobiol Aging 2000; 21: 135–43.
Ebert U, Kirch W. Scopolamine model of dementia: electroencephalo-
gram findings and cognitive performance. Eur J Clin Invest 1998; 28:
944–9.
Fahn S, Elthon RL, and members of the UPDRS Development Committee.
The Unified Parkinson’s Disease Rating Scale. Recent developments in
Parkinson’s disease. Vol. 2. Florham Park, NY: Macmillan Healthcare
Information; 1987. p. 153–63.
Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal
abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. Am J
Roentgenol 1987; 149: 351–6.
Folstein MF, Folstein SE, McHugh PR. ‘‘Mini-mental state’’. A practical
method for grading the cognitive state of patients for the clinician.
J Psychiatr Res 1975; 12: 189–98.
Gagnon JF, Fantini ML, Be´dard MA, Petit D, Carrier J, Rompre S, et al.
Association between waking EEG slowing and REM sleep behavior
disorder in PD without dementia. Neurology 2004; 62: 401–6.
Gasser T, Ba¨cher P, Mo¨cks J. Transformations towards the normal
distribution of broad band spectral parameters of the EEG.
Electroencephalogr Clin Neurophysiol 1982; 53: 119–24.
Gusnard DA, Raichle ME. Searching for a baseline: functional
imaging and the resting human brain. Nat Rev Neurosci 2001; 2:
685–94.
Hobson P, Meara J. The detection of dementia and cognitive impairment
in a community population of elderly people with Parkinson’s disease
Oscillatory brain dynamics in Parkinson’s disease Brain (2007), 130, 1847^1860 1859
 at Vrije Universiteit - Library on November 26, 2010
brain.oxfordjournals.org
D
ow
nloaded from
 
by use of the CAMCOG neuropsychological test. Age Ageing 1999; 28:
39–43.
Honey GD, Suckling J, Zelaya F, Long C, Routledge C, Jackson S, et al.
Dopaminergic drug effects on physiological connectivity in a human
cortico-striato-thalamic system. Brain 2003; 126: 1767–81.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of
idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases.
J Neurol Neurosurg Psychiatry 1992; 55: 181–4.
Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al.
Variable expression of Parkinson’s disease: a base-line analysis of the
DATATOP cohort. Neurology 1990; 40: 1529–34.
Jensen O, Gelfand J, Kounios J, Lisman JE. Oscillations in the alpha band
(9–12 Hz) increase with memory load during retention in a short-term
memory task. Cereb Cortex 2002; 12: 877–82.
Jeong J. EEG dynamics in patients with Alzheimer’s disease. Clin
Neurophysiol 2004; 115: 1490–505.
Klimesch W. EEG alpha and theta oscillations reflect cognitive and
memory performance: a review and analysis. Brain Res Rev 1999; 29:
169–95.
Kotini A, Anninos P, Adamopoulos A, Prassopoulos P. Low-frequency
MEG activity and MRI evaluation in Parkinson’s disease. Brain Topogr
2005; 18: 59–63.
Laufs H, Krakow K, Sterzer P, Eger E, Beyerle A, Salek-Haddadi A, et al.
Electroencephalographic signatures of attentional and cognitive default
modes in spontaneous brain activity fluctuations at rest. Proc Natl Acad
Sci USA 2003; 100: 11053–8.
Mittenecker E. Die Analyse ‘‘zufalliger’’ Reaktionsfolgen. Z Exp Angew
Psychol 1958; 5: 45–60.
Nelson HE, O’Connell A. Dementia: the estimation of premorbid
intelligence levels using the New Adult Reading Test. Cortex 1978; 14:
234–44.
Neufeld MY, Blumen S, Aitkin I, Parmet Y, Korczyn AD. EEG frequency
analysis in demented and nondemented parkinsonian patients.
Dementia 1994; 5: 23–8.
Neufeld MY, Inzelberg R, Korczyn AD. EEG in demented and non-
demented parkinsonian patients. Acta Neurol Scand 1988; 78: 1–5.
Osipova D, Ahveninen J, Kaakkola S, Ja¨a¨skelainen IP, Huttunen J,
Pekkonen E. Effects of scopolamine on MEG spectral power and
coherence in elderly subjects. Clin Neurophysiol 2003; 114: 1902–7.
Peck BK, Vanderwolf CH. Effects of raphe stimulation on
hippocampal and neocortical activity and behaviour. Brain Res 1991;
568: 244–52.
Pezard L, Jech R, Ru˚zˇicˇka E. Investigation of non-linear properties of
multichannel EEG in the early stages of Parkinson’s disease. Clin
Neurophysiol 2001; 112: 38–45.
Posner MI, Petersen SE. The attention system of the human brain. Annu
Rev Neurosci 1990; 13: 25–42.
Raven J, Raven JC, Court JH. Raven manual: section 3. SPM manual
(including the Parallel and Plus Versions). Oxford: Oxford Psychologists
Press; 2000.
Ray PG, Jackson WJ. Lesions of nucleus basalis alter ChAT activity and
EEG in rat frontal neocortex. Electroencephalogr Clin Neurophysiol
1991; 79: 62–8.
Reider CR, Halter CA, Castelluccio PF, Oakes D, Nichols WC, Foroud T.
Reliability of reported age at onset for Parkinson’s disease. Mov Disord
2003; 18: 275–9.
Ricceri L, Minghetti L, Moles A, Popoli P, Confaloni A, De Simone R,
et al. Cognitive and neurological deficits induced by early and prolonged
basal forebrain cholinergic hypofunction in rats. Exp Neurol 2004; 189:
162–72.
Riekkinen P Jr, Sirvio¨ J, Riekkinen M, Riekkinen P. EEG
changes induced by acute and chronic quisqualic or ibotenic acid
nucleus basalis lesions are stabilized by tacridine. Brain Res 1991; 559:
304–8.
Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P.
A neural systems approach to the cognitive psychology of ageing using
the CANTAB battery. In: Rabbit D, editor. Methodology of frontal and
executive function. Hove, UK: Psychology Press; 2002.
Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, et al.
CAMDEX. A standardised instrument for the diagnosis of mental
disorder in the elderly with special reference to the early detection of
dementia. Br J Psychiatry 1986; 149: 698–709.
Schmand B, Bakker D, Saan R, Louman J. The Dutch Reading Test for
Adults: a measure of premorbid intelligence level. Tijdschr Gerontol
Geriatr 1991; 22: 15–9.
Schnitzler A, Gross J. Normal and pathological oscillatory communication
in the brain. Nat Rev Neurosci 2005; 6: 285–96.
Sinanovic O, Kapidzic A, Kovacevic L, Hudic J, Smajlovic D. EEG
frequency and cognitive dysfunction in patients with Parkinson’s
disease. Med Arh 2005; 59: 286–7.
Soikkeli R, Partanen J, Soininen H, Pa¨a¨kkonen A, Riekkinen P Sr. Slowing
of EEG in Parkinson’s disease. Electroencephalogr Clin Neurophysiol
1991; 79: 159–65.
Soininen H, Reinikainen KJ, Partanen J, Helkala EL, Palja¨rvi L,
Riekkinen PJ. Slowing of electroencephalogram and choline acetyltrans-
ferase activity in post mortem frontal cortex in definite Alzheimer’s
disease. Neuroscience 1992; 49: 529–35.
Stam CJ, Jones BF, Manshanden I, van Cappellen van Walsum Am,
Montez T, Verbunt JPA, et al. Magnetoencephalographic evaluation of
resting-state functional connectivity in Alzheimer’s disease. Neuroimage
2006; 32: 1335–44.
Stoffers D, Berendse HW, Deijen JB, Wolters EC. Motor perseveration is
an early sign of Parkinson’s disease. Neurology 2001; 57: 2111–3.
Tanaka H, Koenig T, Pascual-Marqui RD, Hirata K, Kochi K, Lehmann D.
Event-related potential and EEG measures in Parkinson’s disease
without and with dementia. Dement Geriatr Cogn Disord 2000; 11:
39–45.
Timmermann L, Gross J, Dirks M, Volkmann J, Freund HJ, Schnitzler A.
The cerebral oscillatory network of parkinsonian resting tremor. Brain
2003; 126: 199–212.
UNESCO. International Standard Classification of Education 1997.
Montreal: UNESCO Institute of Statistics; 1997.
Van Sweden B, Wauquier A, Niedermeyer E. Normal aging and transient
cognitive disorders in the elderly. In: Niedermeyer E, Lopes Da Silva F,
editors. Electroencephalography: basic principles, clinical applications,
and related fields. Baltimore: Lippincott Williams & Wilkins; 1999.
p. 340–8.
Vanderwolf CH, Baker GB. Evidence that serotonin mediates non-
cholinergic neocortical low voltage fast activity, non-cholinergic
hippocampal rhythmical slow activity and contributes to intelligent
behavior. Brain Res 1986; 374: 342–56.
Vanderwolf CH, Baker GB, Dickson C. Serotonergic control of cerebral
activity and behavior: models of dementia. Ann N Y Acad Sci 1990; 600:
366–82.
Vrba J, Anderson G, Betts K, Burbank MB, Cheung T, Cheyne D, et al.
151-Channel whole-cortex MEG system for seated or supine positions.
In: Yoshimoto T, Kotani M, Kuriki S, Karibe H, Nakasato N, editors.
Recent advances in biomagnetism. Sendai: Tohoku University Press;
1999. p. 93–6.
Ward LM. Synchronous neural oscillations and cognitive processes. Trends
Cogn Sci 2003; 7: 553–9.
Yaar I, Shapiro MB. A quantitative study of the electroencephalographic
response to levodopa treatment in parkinsonian patients. Clin
Electroencephalogr 1983; 14: 82–5.
1860 Brain (2007), 130, 1847^1860 D. Stoffers et al.
 at Vrije Universiteit - Library on November 26, 2010
brain.oxfordjournals.org
D
ow
nloaded from
 
